Enhancement of T cell-mediated and humoral immunity of β-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein

International Journal of Oncology

Volumn 33, Issue 1, 2008, Pages 93-101

  Smahel, Michal ^a   Poláková, Ingrid ^a   Pokorná, Dana ^a   Ludvíková, Viera ^a   Dusková, Martina ^a   Vlasák, Josef ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF PLANT MOLECULAR BIOLOGY   (Czech Republic)

Author keywords

DNA vaccine; E7 oncogene; Human papillomavirus

Indexed keywords

BETA GLUCURONIDASE; DNA VACCINE; PROTEIN E7; HYBRID PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VIRUS ANTIBODY; WART VIRUS VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; FUSION GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; STEADY STATE; TUMOR IMMUNITY; ANIMAL; BLOOD; C57BL MOUSE; CELL STRAIN 3T3; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GLUCURONIDASE; HUMAN PAPILLOMAVIRUS 16; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 51049108409     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.33.1.93     Document Type: Article

References (32)

1. Leifert JA, Rodriguez-Carreno MP, Rodriguez F and Whitton JL: Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 199: 40-53, 2004.
2. zur Hansen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
3. Hung CF, Monie A, Alvarez RD and Wu TC: DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 39: 679-689, 2007.
4. Liu WJ, Gao F, Zhao KN, Zhao W, Fernando GJ, Thomas R and Frazer IH: Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 301: 43-52, 2002.
5. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM and Wu TC: Targeting human papillomavirus type 16 E7 to the endosomal/ lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10: 2727-2740, 1999.
6. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM and Wu TC: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042, 2000.
7. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M and Wu TC: Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61: 3698-3703, 2001.
8. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M and Wu TC: Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166: 5733-5740, 2001.
9. Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001.
10. Smahel M, Sima P, Ludvikova V, Marinov I, Pokoma D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003.
11. Smahel M, Pokorna D, Mackova J and Vlasak J: Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 6: 1092-1101, 2004.
12. Pokorna D, Mackova J, Duskova M, Rittich S, Ludvikova V and Smahel M: Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. J Gene Med 7: 696-707, 2005.
13. Lin KY, Guarnieri FG, Staveley OK, Levitsky HI, August IT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
14. DuBridge RB, Tang P, Hsia. HC, Leong PM, Miller JH and Calos MP: Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387, 1987.
15. Jainchill JL, Aaronson SA and Todaro GJ: Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 4: 549-553, 1969.
16. Kingston RE, Chen CA, Okayama H and Rose JK: Calcium phosphate transfection. In: Current Protocols in Molecular Biology. Ausubel FA, Brent R, Kingston RE, et al (eds.) John Wiley & Sons, New York, pp9.1.4-9.1.11, 1997.
17. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
18. Cho JH, Youn JW and Sung YC: Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 167: 5549-5557, 2001.
19. Li Y, Subjeck J, Yang G, Repasky E and Wang XY: Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 24: 5360-5370, 2006.
20. Cid-Arregui A, Juarez V and zur Hausen H: A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 77: 4928-4937, 2003.
21. Kim MS and Sin JI: Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 116: 255-266, 2005.
22. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H and Muller M: Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294: 47-59, 2002.
23. Shi W, Bu P, Liu J, Polack A, Fisher S and Qiao L: Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73: 7877-7881, 1999.
24. Bins AD, Wolkers MC, van den Boom MD, Haanen JB and Schumacher TN: In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 179: 2126-2133, 2007.
25. Manoj S, Babiuk LA and van Drunen Littel-van den Hurk S: Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci 41: 1-39, 2004.
26. Smotkin D and Wettstein FO: The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J Virol 61: 1686-1689, 1987.
27. Reinstein E, Scheffner M, Oren M, Ciechanover A and Schwartz A: Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19: 5944-5950, 2000.
28. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ and Frazer IH: Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20: 862-869, 2001.
29. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundararn RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE and Brandsma JL: Ubiquitin-fused and/ or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 76: 7616-7624, 2002.
30. Golovina TN, Morrison SE and Eisenlohr LC: The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J Immunol 174: 2763-2769, 2005.
31. Rice J, King CA, Spellerberg MB, Fairweather N and Stevenson FK: Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 17: 3030-3038, 1999.
32. Golovina TN, Wherry EJ, Bullock TN and Eisenlohr LC: Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J Immunol 168: 2667-2675, 2002.